

## Pharmacy Services

(800) 522-0114, option 4

June 27, 2014

RE: Prior Authorization of Sovaldi™, Olysio™, Victrelis®, and Incivek® for the treatment of Hepatitis C

Dear Pharmacist,

The Oklahoma Health Care Authority (OHCA) anticipates that a Prior Authorization requirement will be implemented July 1, 2014 for coverage of **Sovaldi™, Olysio™, Victrelis®, and Incivek®** for the treatment of Hepatitis C.

The PA criteria for these medications can be found at [www.okhca.org/pa](http://www.okhca.org/pa). Click on the link that says "Hepatitis C."

Due to the nature of the treatment regimen and expense, additional documentation is required before authorization will be granted. For each new start, please submit the

- Treatment Initiation Prior Authorization Form
  - Sovaldi™ (PHARM-26); or
  - Olysio™ (PHARM-27)
- Patient Consent and Intent to Treat Contract (PHARM-28)
- Pharmacy Agreement (PHARM-29)

A Continuation of Therapy Form (PHARM-30) is required with each refill to assure the patient is adhering to the prescribed regimen. These forms are required for all patients refilling one of these medications after July 1, 2014. These forms can all be found at [www.okhca.org/rx-forms](http://www.okhca.org/rx-forms).

SoonerCare records indicate your pharmacy NPI has been listed on paid claims for one of these medications (Sovaldi™, Olysio™, Victrelis®, and Incivek®). Any new patient that plans to start on these medications will need the above forms, and any patient who has not completed therapy with these medications will need a Continuation of Therapy Form for their refills to be approved.

If you have any questions please contact the pharmacy help desk at (800) 522-0114, option 4.

Thank you for your continued service to Oklahoma's SoonerCare members.

SoonerCare Pharmacy Services • Pharmacy Management Consultants • PO Box 26901; ORI W-4403 •  
Oklahoma City, Oklahoma 73126-0901 • Phone: (800) 522-0114, option 4 • Fax: (800) 224-4014

This transmission and any documents or files accompanying it may contain confidential information. This may include patient medical information that is protected under State and Federal laws. The information in this transmission is intended only for the delivery to the individual or entity named on the attached sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this transmission is strictly prohibited and may be in violation of law. If you have received this transmission in error, please notify the sender immediately, to arrange for the return of the documents or deletion of the transmission.

# Hepatitis C Therapy Continuation Prior Authorization Form

Member Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Member ID#: \_\_\_\_\_  
Pharmacy Name: \_\_\_\_\_ Pharmacy NPI: \_\_\_\_\_  
Pharmacy Phone: \_\_\_\_\_ Pharmacy Fax: \_\_\_\_\_  
Pharmacist Name: \_\_\_\_\_ Prescriber Name: \_\_\_\_\_  
Prescriber NPI: \_\_\_\_\_ Specialty: \_\_\_\_\_  
Prescriber Phone: \_\_\_\_\_ Prescriber Fax: \_\_\_\_\_

## Pharmacy Section

Member's Hepatitis C Therapy Regimen: \_\_\_\_\_

Drug Name: \_\_\_\_\_ NDC: \_\_\_\_\_

Today's Date: \_\_\_\_\_ Date Prescription Last Filled: \_\_\_\_\_  
Date Member Took First Dose: \_\_\_\_\_ Expected End Date: \_\_\_\_\_

Number of doses remaining today: \_\_\_\_\_ Refill Number: \_\_\_\_\_

Did the member fill pegylated interferon? Yes \_\_\_\_\_ No \_\_\_\_\_  
Date pegylated interferon last filled: \_\_\_\_\_ Remaining Supply: \_\_\_\_\_

Did the member fill ribavirin? Yes \_\_\_\_\_ No \_\_\_\_\_  
Date ribavirin last filled: \_\_\_\_\_ Remaining Supply: \_\_\_\_\_

Pharmacist Signature: \_\_\_\_\_ Date: \_\_\_\_\_

## Prescriber Section

Initial Viral Load \_\_\_\_\_ Date Tested: \_\_\_\_\_

Recent Viral Load \_\_\_\_\_ Date Tested: \_\_\_\_\_

Recent Urine Drug Screen? Yes \_\_\_\_\_ No \_\_\_\_\_ Date Tested: \_\_\_\_\_

Monthly Pregnancy Test? \*\* Yes \_\_\_\_\_ No \_\_\_\_\_ NA \_\_\_\_\_ Date Tested: \_\_\_\_\_

\*\*Required for female members and female partners of male members.

Has the member experience any adverse drug reactions related to hepatitis C therapy?

Yes \_\_\_\_\_ No \_\_\_\_\_

If yes, please specify reactions: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Please do not send in chart notes. Specific information/documentation will be requested if necessary.

### PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy  
Pharmacy Management Consultants  
Product Based Prior Authorization Unit

Fax: 1-800-224-4014  
Phone: 1-800-522-0114 Option 4

### CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.